Neurochemical Research

, Volume 36, Issue 2, pp 223–231 | Cite as

6-Hydroxydopamine-Induced PC12 Cell Death is Mediated by MEF2D Down-regulation

  • Min-Kyoung Kim
  • Sang-Cheol Kim
  • Jung-Il Kang
  • Jae-Hee Hyun
  • Hye-Jin Boo
  • Su-Yong Eun
  • Deok-Bae Park
  • Eun-Sook Yoo
  • Hee-Kyoung Kang
  • Ji-Hoon Kang


Recently, it was reported that in a 4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model, neuronal cell death is associated with the cdk5-mediated hyperphosphorylation of myocyte enhancer factor 2 (MEF2), a transcription factor that is critically required for neuronal survival. In the present study, we investigated the possible involvement of cdk5-mediated MEF2D down-regulation on 6-hydroxydopamine (6-OHDA)-induced PC12 cell death. 6-OHDA was found to significantly increase nitric oxide (NO) production and to induce apoptosis in a time-dependent manner in PC12 cells. Furthermore, 6-OHDA was found to markedly reduce MEF2D levels under conditions that could induce PC12 cell apoptosis. In addition, PC12 cell death and MEF2D degradation by 6-OHDA were prevented by the cdk5 inhibitor roscovitine, but roscovitine could not restore the 6-OHDA-induced inactivation of Akt. These results suggest that the cell death and MEF2D degradation caused by 6-OHDA are dependent on cdk5 activity. On the other hand, roscovitine enhanced the 6-OHDA-induced activations of ERK1/2 and JNK, but reduced the 6-OHDA-induced activation of p38. These results suggest that PC12 cell death by 6-OHDA appears to be regulated by the down-regulation of MEF2D via some interaction between cdk5 and MAP kinase.


6-OHDA PC12 cells NO MEF2D cdk5 MAP kinase 



This work was supported by a research grant from Jeju National University in 2007.


  1. 1.
    Lyons GE, Micales BK, Schwarz J et al (1995) Expression of mef2 genes in the mouse central nervous system suggests a role in neuronal maturation. J Neurosci 15:5727–5738PubMedGoogle Scholar
  2. 2.
    McKinsey TA, Zhang CL, Olson EN (2002) MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem Sci 27:40–47CrossRefPubMedGoogle Scholar
  3. 3.
    Shalizi AK, Bonni A (2005) Brawn for brains: the role of MEF2 proteins in the developing nervous system. Curr Top Dev Biol 69:239–266CrossRefPubMedGoogle Scholar
  4. 4.
    Black BL, Olson EN (1998) Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. Annu Rev Cell Dev Biol 14:167–196CrossRefPubMedGoogle Scholar
  5. 5.
    Mao Z, Bonni A, Xia F et al (1999) Neuronal activity-dependent cell survival mediated by transcription factor MEF2. Science 286:785–790CrossRefPubMedGoogle Scholar
  6. 6.
    Mao Z, Wiedmann M (1999) Calcineurin enhances MEF2 DNA binding activity in calcium-dependent survival of cerebellar granule neurons. J Biol Chem 274:31102–31107CrossRefPubMedGoogle Scholar
  7. 7.
    Okamoto S, Krainc D, Sherman K et al (2000) Antiapoptotic role of the p38 mitogen-activated protein kinase-myocyte enhancer factor 2 transcription factor pathway during neuronal differentiation. Proc Natl Acad Sci USA 97:7561–7566CrossRefPubMedGoogle Scholar
  8. 8.
    Li M, Linseman DA, Allen MP et al (2001) Myocyte enhancer factor 2A and 2D undergo phosphorylation and caspase-mediated degradation during apoptosis of rat cerebellar granule neurons. J Neurosci 21:6544–6552PubMedGoogle Scholar
  9. 9.
    Gong X, Tang X, Wiedmann M et al (2003) Cdk5-mediated inhibition of the protective effects of transcription factor MEF2 in neurotoxicity-induced apoptosis. Neuron 38:33–46CrossRefPubMedGoogle Scholar
  10. 10.
    Liu L, Cavanaugh JE, Wang Y et al (2003) ERK5 activation of MEF2-mediated gene expression plays a critical role in BDNF-promoted survival of developing but not mature cortical neurons. Proc Natl Acad Sci USA 100:8532–8537CrossRefPubMedGoogle Scholar
  11. 11.
    Gaudilliere B, Shi Y, Bonni A (2002) RNA interference reveals a requirement for myocyte enhancer factor 2A in activity-dependent neuronal survival. J Biol Chem 277:46442–46446CrossRefPubMedGoogle Scholar
  12. 12.
    Linseman DA, Bartley CM, Le SS et al (2003) Inactivation of the myocyte enhancer factor-2 repressor histone deacetylase-5 by endogenous Ca (2 +)/calmodulin-dependent kinase II promotes depolarization-mediated cerebellar granule neuron survival. J Biol Chem 278:41472–41481CrossRefPubMedGoogle Scholar
  13. 13.
    Flavell SW, Cowan CW, Kim TK et al (2006) Activity-dependent regulation of MEF2 transcription factors suppresses excitatory synapse number. Science 311:1008–1012CrossRefPubMedGoogle Scholar
  14. 14.
    Shalizi A, Gaudillière B, Yuan Z et al (2006) A calcium-regulated MEF2 sumoylation switch controls postsynaptic differentiation. Science 311:1012–1017CrossRefPubMedGoogle Scholar
  15. 15.
    Shalizi A, Bilimoria PM, Stegmüller J et al (2007) PIASx is a MEF2 SUMO E3 ligase that promotes postsynaptic dendritic morphogenesis. J Neurosci 27:10037–10046CrossRefPubMedGoogle Scholar
  16. 16.
    Tang X, Wang X, Gong X et al (2005) Cyclin-Dependent Kinase 5 Mediates Neurotoxin-Induced Degradation of the Transcription Factor Myocyte Enhancer Factor 2. J Neurosci 25:4823–4834CrossRefPubMedGoogle Scholar
  17. 17.
    Smith PD, Mount MP, Shree R et al (2006) Calpain-regulated p35/cdk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2. J Neurosci 26:440–447CrossRefPubMedGoogle Scholar
  18. 18.
    Saito Y, Nishio K, Ogawa Y et al (2007) Molecular mechanisms of 6-hydroxydopamine-induced cytotoxicity in PC12 cells: involvement of hydrogen peroxide-dependent and -independent action. Free Radic Biol Med 42:675–685CrossRefPubMedGoogle Scholar
  19. 19.
    Nicholson DW, Ali A, Thornberry NA et al (1995) Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376:37–43CrossRefPubMedGoogle Scholar
  20. 20.
    Singh S, Kumar S, Dikshit M (2010) Involvement of the mitochondrial apoptotic pathway and nitric oxide synthase in dopaminergic neuronal death induced by 6-hydroxydopamine and lipopolysaccharide. Redox Rep 15:115–122PubMedGoogle Scholar
  21. 21.
    Cohen G, Heikkila RE (1974) The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. J Biol Chem 249:2447–2452PubMedGoogle Scholar
  22. 22.
    Liu X, Shibata T, Hisaka S, Osawa T (2009) Astaxanthin inhibits reactive oxygen species-mediated cellular toxicity in dopaminergic SH-SY5Y cells via mitochondria-targeted protective mechanism. Brain Res 1254:18–27CrossRefPubMedGoogle Scholar
  23. 23.
    Bové J, Prou D, Perier C et al (2005) Toxin-induced models of Parkinson’s disease. NeuroRx 2:484–494CrossRefPubMedGoogle Scholar
  24. 24.
    Blum D, Torch S, Lambeng N et al (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson’s disease. Prog Neurobiol 65:135–172CrossRefPubMedGoogle Scholar
  25. 25.
    Gerlach M, Riederer P (1996) Animal models of Parkinson’s disease: an empirical comparison with the phenomenology of the disease in man. J neural Trans 103:987–1041CrossRefGoogle Scholar
  26. 26.
    Sauer H, Oertel WH (1994) Progressive degeneration of nigrostriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59:401–415CrossRefPubMedGoogle Scholar
  27. 27.
    Heikkila R, Cohen G (1971) Inhibition of biogenic amine uptake by hydrogen peroxide: a mechanism for toxic effects of 6-hydroxydopamine. Science 172:1257–1258CrossRefPubMedGoogle Scholar
  28. 28.
    Permual AS, Tordzro WK, Katz M et al (1989) Regional effects of 6-hydroxydopamine on free radical scavengers in the rat brain. Brain Res 504:139–141CrossRefGoogle Scholar
  29. 29.
    Permual AS, Gopal VB, Tordzro WK et al (1992) Vitamin E attenuates the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain. Brain Res Bull 29:699–701CrossRefGoogle Scholar
  30. 30.
    Kumar R, Agarwal ML, Seth PK (1995) Free radical-generated neurotoxicity of 6-hydroxydopamine. J Neurochem 64:1703–1707CrossRefPubMedGoogle Scholar
  31. 31.
    Tiffany-Castiglioni E, Saneto RP, Proctor PH et al (1982) Participation of active oxygen species in 6-hydroxydopamine toxicity to a human neuroblastoma cell line. Biochem Pharmacol 31:181–188CrossRefPubMedGoogle Scholar
  32. 32.
    Decker DE, Althaus JS, Buxser SE et al (1993) Competitive irreversible inhibition of dopamine uptake by 6-hydroxydopamine. Res Commun Chem Pathol Pharmacol 79:195–208PubMedGoogle Scholar
  33. 33.
    Abad F, Maroto R, Lopez MG et al (1995) Pharmacological protection against the cytotoxicity of 6-hydroxydopamine and H2O2 in chromaffin cells. Eur J Pharmacol 293:55–64CrossRefPubMedGoogle Scholar
  34. 34.
    Choi WS, Yoon SY, Oh TH et al (1999) Two distinct mechanisms are involved in 6-hydroxydopamine- and MPP+-induced dopaminergic cell death: role of caspases, ROS and JNK. J Neurosci Res 57:86–94CrossRefPubMedGoogle Scholar
  35. 35.
    Lotharius J, Dugan LL, O’Malley KL (1999) Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J Neurosci 19:1284–1293PubMedGoogle Scholar
  36. 36.
    Sharma P, Veeranna A, Sharma P, Sharma M et al (2002) Phosphorylation of MEK1 by cdk5/p35 down-regulates the mitogen-activated protein kinase pathway. J Biol Chem 277:528–534CrossRefPubMedGoogle Scholar
  37. 37.
    Harada T, Morooka T, Ogawa S et al (2001) ERK induces p35, a neuron-specific activator of Cdk5, through induction of Egr1. Nat Cell Biol 3:453–459CrossRefPubMedGoogle Scholar
  38. 38.
    Takai N, Nakanishi H, Tanabe K et al (1998) Involvement of caspase-like proteinases in apoptosis of neuronal PC12 cells and primary cultured microglia induced by 6-hydroxydopamine. J Neurosci Res 54:214–222CrossRefPubMedGoogle Scholar
  39. 39.
    Zheng YL, Li BS, Kanungo J et al (2006) Cdk5 modulation of mitogen-activated protein kinase signaling regulates neuronal survival. Mol Biol Cell 18:404–413CrossRefPubMedGoogle Scholar
  40. 40.
    Li BS, Zhang L, Takahashi S et al (2002) Cyclin-dependent kinase 5 prevents neuronal apoptosis by negative regulation of c-Jun N-terminal kinase 3. EMBO J 21:324–333CrossRefPubMedGoogle Scholar
  41. 41.
    Nikolic M, Chou MM, Lu W et al (1998) The p35/Cdk5 kinase is a neuron-specific Rac effector that inhibits Pak1 activity. Nature 395:194–198CrossRefPubMedGoogle Scholar
  42. 42.
    Shetty KT, Veeranna A, Takahashi M et al (2000) Cdk5 and MAPK are associated with complexes of cytoskeletal proteins in rat brain. Brain Res Mol Brain Res 76:229–236PubMedGoogle Scholar
  43. 43.
    Brunet A, Datta SR, Greenberg ME (2001) Transcription-dependent and -independent control of neuronal survival by the PI3 K–Akt signaling pathway. Curr Opin Neurobiol 11:297–305CrossRefPubMedGoogle Scholar
  44. 44.
    Chong ZZ, Li F, Maiese K (2005) Activating Akt and the brain’s resources to drive cellular survival and prevent inflammatory injury. Histol Histopathol 20:299–315PubMedGoogle Scholar
  45. 45.
    Kulich SM, Horbinski C, Patel M et al (2007) 6-Hydroxydopamine induces mitochondrial ERK activation. Free Radic Biol Med 43:372–383CrossRefPubMedGoogle Scholar
  46. 46.
    Jiang Z, Yu PH (2005) Involvement of extracellular signal-regulated kinases 1/2 and (phosphoinositide 3-kinase)/Akt signal pathways in acquired resistance against neurotoxin of 6-hydroxydopamine in SH-SY5Y cells following cell-cell interaction with astrocytes. Neuroscience 133:405–411CrossRefPubMedGoogle Scholar
  47. 47.
    Smith PD, O’Hare MJ, Park DS (2004) Emerging pathogenic role for cyclin dependent kinases in neurodegeneration. Cell Cycle 3:289–291PubMedGoogle Scholar
  48. 48.
    Subramaniam S, Unsicker K (2006) Extracellular signal-regulated kinase as an inducer of non-apoptotic neuronal death. Neuroscience 138:1055–1065CrossRefPubMedGoogle Scholar
  49. 49.
    Sako K, Fukuhara S, Minami T et al (2008) Angiopoietin-1 induces Kruppel-like factor 2 expression through a phosphoinositide 3-kinase/AKT-dependent activation of myocyte enhancer factor 2. J Biol Chem 284:5592–5601CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Min-Kyoung Kim
    • 1
  • Sang-Cheol Kim
    • 1
  • Jung-Il Kang
    • 1
  • Jae-Hee Hyun
    • 1
  • Hye-Jin Boo
    • 1
  • Su-Yong Eun
    • 2
  • Deok-Bae Park
    • 3
  • Eun-Sook Yoo
    • 1
  • Hee-Kyoung Kang
    • 1
  • Ji-Hoon Kang
    • 4
  1. 1.Department of Pharmacology, School of Medicine, Institute of Medical SciencesJeju National UniversityJejuSouth Korea
  2. 2.Department of Physiology, School of Medicine, Institute of Medical SciencesJeju National UniversityJejuSouth Korea
  3. 3.Department of Histology, School of Medicine, Institute of Medical SciencesJeju National UniversityJejuSouth Korea
  4. 4.Department of Neurology, School of Medicine, Institute of Medical SciencesJeju National UniversityJejuSouth Korea

Personalised recommendations